All the news

Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ...

Treatment with sofosbuvir/ledipasvir (Harvoni) was well tolerated and cured all pregnant women with hepatitis C virus (HCV), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) ...

Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with hepatitis C, according to results of one of the largest studies ...

Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ...

Almost all young children ages 3 to 6 years with chronic hepatitis C achieved sustained virological response after 12 weeks of treatment using sofosbuvir/ledipasvir oral granules, according to findings presented at the ...

Treatment for hepatitis C, especially if it leads to a cure, is associated with a reduced risk of cardiovascular events such as congestive heart failure, heart attacks and strokes, according to research presented ...